A phase 1/2, open-label assessment of the safety, tolerability, and efficacy of transdermal cannabidiol (ZYN002) for the treatment of pediatric fragile X syndrome

BACKGROUND: Fragile X syndrome (FXS) is characterized by a range of developmental, neuropsychiatric, and behavioral symptoms that cause significant impairment in those with the disorder. Cannabidiol (CBD) holds promise as a potential treatment for FXS symptoms due to its safety profile and positive...

Descripción completa

Detalles Bibliográficos
Autores principales: Heussler, Helen, Cohen, Jonathan, Silove, Natalie, Tich, Nancy, Bonn-Miller, Marcel O., Du, Wei, O’Neill, Carol, Sebree, Terri
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6676516/
https://www.ncbi.nlm.nih.gov/pubmed/31370779
http://dx.doi.org/10.1186/s11689-019-9277-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6676516/
https://www.ncbi.nlm.nih.gov/pubmed/31370779
http://dx.doi.org/10.1186/s11689-019-9277-x

Ejemplares similares